267 related articles for article (PubMed ID: 30679646)
1. Immunoinformatic and systems biology approaches to predict and validate peptide vaccines against Epstein-Barr virus (EBV).
Ali A; Khan A; Kaushik AC; Wang Y; Ali SS; Junaid M; Saleem S; Cho WCS; Mao X; Wei DQ
Sci Rep; 2019 Jan; 9(1):720. PubMed ID: 30679646
[TBL] [Abstract][Full Text] [Related]
2. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
3. Computer-Aided Design of an Epitope-Based Vaccine against Epstein-Barr Virus.
Alonso-Padilla J; Lafuente EM; Reche PA
J Immunol Res; 2017; 2017():9363750. PubMed ID: 29119120
[TBL] [Abstract][Full Text] [Related]
4. Contriving multiepitope subunit vaccine by exploiting structural and nonstructural viral proteins to prevent Epstein-Barr virus-associated malignancy.
Ojha R; Nandani R; Prajapati VK
J Cell Physiol; 2019 May; 234(5):6437-6448. PubMed ID: 30362500
[TBL] [Abstract][Full Text] [Related]
5. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
6. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
Khanna R; Burrows SR; Kurilla MG; Jacob CA; Misko IS; Sculley TB; Kieff E; Moss DJ
J Exp Med; 1992 Jul; 176(1):169-76. PubMed ID: 1377222
[TBL] [Abstract][Full Text] [Related]
7. mRNA-Based Vaccine Designing against Epstein-Barr Virus to Induce an Immune Response Using Immunoinformatic and Molecular Modelling Approaches.
Althurwi HN; Alharthy KM; Albaqami FF; Altharawi A; Javed MR; Muhseen ZT; Tahir Ul Qamar M
Int J Environ Res Public Health; 2022 Oct; 19(20):. PubMed ID: 36293632
[TBL] [Abstract][Full Text] [Related]
8. Immunoinformatics Approach to Design Novel Subunit Vaccine against the Epstein-Barr Virus.
Moin AT; Patil RB; Tabassum T; Araf Y; Ullah MA; Snigdha HJ; Alam T; Alvey SA; Rudra B; Mina SA; Akter Y; Zhai J; Zheng C
Microbiol Spectr; 2022 Oct; 10(5):e0115122. PubMed ID: 36094198
[TBL] [Abstract][Full Text] [Related]
9. Prediction and validation of potent peptides against herpes simplex virus type 1 via immunoinformatic and systems biology approach.
Mehmood A; Kaushik AC; Wei DQ
Chem Biol Drug Des; 2019 Sep; 94(5):1868-1883. PubMed ID: 31437863
[TBL] [Abstract][Full Text] [Related]
10. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
Khanna R; Burrows SR; Moss DJ; Silins SL
J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
[TBL] [Abstract][Full Text] [Related]
11. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
[TBL] [Abstract][Full Text] [Related]
12. Membrane anchoring of Epstein-Barr virus gp42 inhibits fusion with B cells even with increased flexibility allowed by engineered spacers.
Rowe CL; Chen J; Jardetzky TS; Longnecker R
mBio; 2015 Jan; 6(1):. PubMed ID: 25564465
[TBL] [Abstract][Full Text] [Related]
13. The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation.
Tynan FE; Elhassen D; Purcell AW; Burrows JM; Borg NA; Miles JJ; Williamson NA; Green KJ; Tellam J; Kjer-Nielsen L; McCluskey J; Rossjohn J; Burrows SR
J Exp Med; 2005 Nov; 202(9):1249-60. PubMed ID: 16275762
[TBL] [Abstract][Full Text] [Related]
14. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
Khanna R; Burrows SR; Nicholls J; Poulsen LM
Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
[TBL] [Abstract][Full Text] [Related]
15. Survey of Epstein Barr virus (EBV) immunogenic proteins and their epitopes: implications for vaccine preparation.
Rajcani J; Szenthe K; Banati F; Szathmary S
Recent Pat Antiinfect Drug Discov; 2014; 9(1):62-76. PubMed ID: 25164057
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
17. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
18. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation.
Khanna R; Moss DJ; Burrows SR
Immunol Rev; 1999 Aug; 170():49-64. PubMed ID: 10566141
[TBL] [Abstract][Full Text] [Related]
19. Contrasting Epstein-Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design.
Bharadwaj M; Sherritt M; Khanna R; Moss DJ
Vaccine; 2001 Jun; 19(27):3769-77. PubMed ID: 11395212
[TBL] [Abstract][Full Text] [Related]
20. Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression.
Kienzle N; Sculley TB; Poulsen L; Buck M; Cross S; Raab-Traub N; Khanna R
J Virol; 1998 Aug; 72(8):6614-20. PubMed ID: 9658107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
